ATLAS-2M, Wk 96 Results: Long-Acting Injectable Cabotegravir + Rilpivirine Every 8 Wks Is Noninferior to Every 4 Wks

March 6-10, 2021; Virtual
Long-acting cabotegravir plus rilpivirine injections every 2 months are noninferior to monthly injections at Week 96 in virologically suppressed patients with no prior virologic failure.
Format: Microsoft PowerPoint (.ppt)
File Size: 172 KB
Released: March 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options’ (CCO) commentary from a person with HIV on what it was like living through the COVID-19 pandemic as a long-term HIV survivor

person default Frank Primavera Released: June 9, 2021

CCO slides from Drs. Joseph J. Eron, Jr, and Darcy Wooten on the implications of emerging ART safety and tolerability data when managing HIV treatment

Joseph J. Eron, Jr., MD Darcy Wooten, MD Released: May 11, 2021

Clinical Care Options (CCO) presents Howard Grossman, MD, and Cristina Mussini, MD, answering questions on HIV prevention in older individuals

Howard Grossman, MD Cristina Mussini, MD Released: May 6, 2021

Download free expert-authored slides to see how clinicians use HIV-ASSIST to choose appropriate, guideline-based antiretroviral therapy

Jehan Budak, MD Ethel D. Weld, MD, PhD Released: April 26, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue